mg-1

MG 1 is a potent alpha-1 adrenergic receptor antagonist.

Anti-mouse ICOSL/CD275 antibody, targeting ICOSL/CD275.

DSPE-PEG3400-MG1 is a PEG compound composed of DSPE and the MG1 peptide. The MG1 peptide serves as a microglial M1 cell-targeting peptide. It can conjugate with nanoparticles to cross the blood-brain barrier, accurately target M1 microglial cells, and achieve controlled drug release and specific accumulation through an intelligent molecular switch. DSPE-PEG3400-MG1 is suitable for drug delivery.

DSPE-PEG5000-MG1 is a PEG compound consisting of DSPE and the MG1 peptide. The MG1 peptide targets M1 microglia cells, allowing it to conjugate with nanoparticles to cross the blood-brain barrier. This enables precise recognition of M1 microglia cells and facilitates controlled drug release and specific accumulation through an intelligent molecular switch. DSPE-PEG5000-MG1 is useful for drug delivery.

DSPE-PEG2000-MG1 is a PEG compound composed of DSPE and the MG1 peptide. The MG1 peptide is an M1 microglia-targeting peptide that can couple with nanoparticles to traverse the blood-brain barrier, precisely recognize M1 microglia, and enable controlled drug release and specific accumulation via a smart molecular switch. DSPE-PEG2000-MG1 is utilized for drug delivery.

DSPE-PEG1000-MG1 is a PEG compound composed of DSPE and the MG1 peptide. The MG1 peptide is a microglia M1-targeting peptide. It can conjugate with nanoparticles, facilitating passage through the blood-brain barrier to accurately identify M1 microglia, and enables controlled release and specific accumulation of drugs via a smart molecular switch. DSPE-PEG1000-MG1 is applicable in drug delivery.

MG1 peptide is a targeting peptide for M1 microglial cells. It can be conjugated with nanoparticles to traverse the blood-brain barrier, accurately identify M1 microglial cells, and enable controlled drug release and specific accumulation through an intelligent molecular switch. MG1 peptide is applicable in drug delivery research for ischemic stroke.

MG-132 (Z-Leu-Leu-Leu-al) is a 26S proteasome inhibitor (IC50=100 nM) that is cell-permeable and reversible. MG-132 acts as an autophagy activator and also induces apoptosis.

AMG-1694, a potent disruptor of the glucokinase–glucokinase regulatory protein (GK-GKRP) complex, operates by promoting the dissociation of this complex, thereby indirectly enhancing GK enzymatic activity with an IC50 of 7 nM. It effectively normalizes blood glucose levels in various rodent diabetes models [1] and lowers blood glucose specifically in diabetic animals without affecting normoglycemic ones. Additionally, AMG-1694 reverses the GKRP-induced inhibition of GK activity and facilitates GK translocation.

hSMG-1 inhibitor 11e is an effective and selective inhibitor of hSMG-1 (IC50 <0.05 nM) and can be used in studies about cancer treatment.

hSMG-1 inhibitor 11j is a pyrimidine derivative. hSMG-1 inhibitor 11j is a potent and selective inhibitor of hSMG-1, IC50 = 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer.

KMG-104 is a selective Mg2+ fluorescent probe for dynamic observation of Mg2+ in the cytoplasm of living cells.

MG-115 (Z-LL-Nva-CHO) is a potent and reversible inhibitor of proteasome , with K i s of 21 nM and 35 nM for 20S and 26S proteasome, respectively. MG-115 specifically inhibit the chymotrypsin-like activity of the proteasome, induces p53-dependent apoptosis [1] [2] [3].

MG-101 (Calpain inhibitor I) is a cell-permeable and potent inhibitor of cysteine proteases including calpains and lysosomal cathepsins.

MG-1102 is a first-in-class dual binder of monomeric tau and pre-miRNA-146a, exhibiting specific inhibition of miRNA146a with IC 50 values of 0.21 mM for double-labeled pre-miRNA146a and 0.36 mM for mono-labeled pre-miRNA146a. It interacts with tau monomers with a K d of 3.21 mM as determined by surface plasmon resonance (SPR), positioning it as a potential multi-target-directed ligand (MTDL) for Alzheimer's disease (AD) [1].

(R)-MG-132 (Z-Leu-D-leu-leu-al) is the enantiomer of MG-132.

MMG-11 inhibits both TLR2/1 and TLR2/6 signaling (IC50s: 1.7 μM for Pam3CSK4-induced hTLR2/1 and 5.7 μM for Pam2CSK4-induced hTLR2/6 responses). MMG-11 is an effective and selective human TLR2 antagonist with low cytotoxicity.

KMG-1068 (Compound 4a), a molecular glue, acts as a GSPT1/2 degrader. By binding to the IMiD binding site on CRBN, KMG-1068 efficiently induces CRBN-dependent degradation of GSPT1/2 and facilitates the formation of a ternary complex with GSPT1/2. KMG-1068 holds potential for use in cancer research.

MMG-1, a monoalkylglycerol, acts as a C-type lectin receptor agonist and stabilizes lipid membranes. It functions as an immune adjuvant in liposomes and is useful in formulating lipid nanoparticles for drug delivery.

AMG-126737 is an effective human lung mast cell trypsin inhibitor with potential therapeutic effect in lung diseases.

MMG-11 quarterhydrate is a potent and selective antagonist of human TLR2, inhibiting both TLR2/1 and TLR2/6 signaling with low cytotoxicity. The IC50 values for Pam3CSK4-induced hTLR2/1 and Pam2CSK4-induced hTLR2/6 responses are 1.7 μM and 5.7 μM, respectively [1].

AMG-1 is a specific CRAC channel inhibitor. AMG-1 blocks the function of effector T cells, but not regulatory T cells in vitro and it attenuates the progression and severity of EAE in vivo.

AMG-131 besylate is a hypoglycemic agent. It is a potent PPARγ partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs.

AMG-193 is an inhibitor of the MTA-PRMT5 complex and is used in the study of cancer, respiratory diseases and digestive disorders.